-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on BridgeBio Oncology, Lowers Price Target to $13

Benzinga·10/21/2026 15:58:06
Listen to the news
Morgan Stanley analyst Sean Laaman maintains BridgeBio Oncology (NASDAQ:BBOT) with a Overweight and lowers the price target from $18 to $13.